Skip to main content
BALAXI PHARMACEUTICALS LIMITED logo

BALAXI PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · BALAXI ISIN · INE618N01022 LEI · 894500VRENAYIIWHHQ13 National Stock Exchange of India Wholesale and retail trade
Open in API
Filings indexed 615 across all filing types
Latest filing 2024-05-29 Regulatory Filings
Country IN India
Listing National Stock Exchange of India BALAXI

About BALAXI PHARMACEUTICALS LIMITED

https://www.balaxipharma.in/

Balaxi Pharmaceuticals Limited is a specialty pharmaceutical company that operates an asset-light business model focused on sourcing, branding, and distributing generic formulations in frontier markets. The company primarily serves emerging economies across Africa and Latin America, including Angola, Guatemala, and the Dominican Republic. Its product portfolio encompasses a wide range of therapeutic segments such as anti-infectives, analgesics, and antimalarials. Balaxi manages an integrated supply chain, leveraging its regulatory expertise to register and market high-quality pharmaceutical products. By maintaining a robust distribution network and localized presence, the company ensures the availability of essential medicines in underserved regions while optimizing operational efficiency through its specialized procurement and logistics framework.

Recent filings

Filing Released Lang Actions
Statement of deviation(s) or variation(s) under Reg. 32
Regulatory Filings Classification · 95% confidence The document is a statement addressed to the National Stock Exchange of India regarding the deviation or variation in the utilization of funds raised through a preferential issue for the quarter ended March 31, 2024. It references SEBI regulations and provides detailed information about the fund raising, utilization, and any deviations. The content is regulatory in nature, reporting compliance with disclosure requirements rather than presenting a full financial report or earnings release. The document is relatively short (4422 characters) and serves as a formal regulatory disclosure rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2024-05-29 English
Appointment
Board/Management Information Classification · 100% confidence The document is an official communication addressed to the National Stock Exchange of India Limited regarding the appointment of Mr. Mahesh Inani as the Company Secretary and Compliance Officer of Balaxi Pharmaceuticals Limited. It references SEBI regulations and provides details about the appointment, including a brief profile of the appointee. There are no financial statements, earnings data, or report publications included. The content focuses on a change in senior management personnel, specifically the appointment of a key managerial person. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 5070 characters, which is consistent with a detailed management announcement rather than a full report or regulatory filing.
2024-05-29 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from the Board of Directors of Balaxi Pharmaceuticals Limited dated May 29, 2024. It includes the approval and disclosure of the Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31, 2024, accompanied by the Audit Report from the Statutory Auditors. The document also mentions the re-appointment of Internal Auditors and updates on a pharmaceutical plant project. The financial results include detailed income statements, balance sheets, and notes prepared under Indian Accounting Standards. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not just an announcement or summary. It is not a mere report publication announcement or certification. Therefore, this document is best classified as an Interim / Quarterly Report (IR) because it covers quarterly and annual audited financial results but is not a full annual report (10-K). The presence of quarterly and year-end audited results aligns with the definition of an Interim / Quarterly Report.
2024-05-29 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed announcement dated May 29, 2024, from Balaxi Pharmaceuticals Limited regarding the outcome of a Board Meeting. It includes approval of standalone and consolidated audited financial results for the quarter and year ended March 31, 2024, accompanied by the audit report from statutory auditors. The document contains extensive financial data including income, expenses, profit/loss, assets, liabilities, and equity details. It also mentions compliance with SEBI regulations and includes notes on accounting standards and segment reporting. The presence of full audited financial statements and audit opinions indicates this is a comprehensive financial report for the fiscal year ending March 31, 2024. This matches the definition of an Annual Report (10-K) type filing, as it covers the full financial performance and activity of the company for the year. The document is not merely an announcement or a certification but contains substantive financial data and analysis. Therefore, the correct classification is Annual Report (10-K).
2024-05-29 English
Board Meeting — BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2024 to consider and approve the Yearly Audited Financial results of the Company for…
Regulatory Filings
2024-05-21 English
Board Meeting — Financial Results
Board/Management Information Classification · 95% confidence The document is a short notice addressed to the stock exchange about an upcoming Board Meeting scheduled to approve audited financial results for the quarter and year ended March 31, 2024. It also mentions the closure of the trading window as per insider trading regulations. The document does not contain any financial data or results itself, nor does it include detailed financial statements or analysis. It is an announcement of a future event (Board Meeting) and related compliance information. The document length is only 1750 characters, which is quite short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of Board/Management Information (MANG), as it relates to informing about a Board Meeting and related regulatory compliance.
2024-05-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.